ES2178634T3 - Peptidos analogos de cnp y su utilizacion. - Google Patents

Peptidos analogos de cnp y su utilizacion.

Info

Publication number
ES2178634T3
ES2178634T3 ES92101621T ES92101621T ES2178634T3 ES 2178634 T3 ES2178634 T3 ES 2178634T3 ES 92101621 T ES92101621 T ES 92101621T ES 92101621 T ES92101621 T ES 92101621T ES 2178634 T3 ES2178634 T3 ES 2178634T3
Authority
ES
Spain
Prior art keywords
ser
arg
gly
phe
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92101621T
Other languages
English (en)
Inventor
Shoji Tanaka
Yoshiharu Minamitake
Yasuo Kitajima
Mayumi Furuya
Hisayuki Matsuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2178634T3 publication Critical patent/ES2178634T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTAN NUEVOS PEPTIDOS REPRESENTADOS POR LA FORMULA GENERAL: Y LAS SALES DE ADICION ACIDAS FISIOLOGICAMENTE ACEPTABLES DE LOS MISMOS; DONDE (A) REPRESENTA H-, H-GLY, H-LYS-GLY, H-SER-LYS-GLY, H-LEU-SER-LYS-GLY, H-GLY-LEU-SER-LYS-GLY, H-SER, H-SER-SER, H-ARG-SER-SER, H-ARG-ARG-SER-SER, H-LEU-ARG-ARG-SER-SER, H-SER-LEU-ARG-ARG-SER-SER; (B) REPRESENTA H-CYS O PMP; (C) REPRESENTA PHE-, PC LANDA-PHE, PF-PHE, PNO SUB 2-PHE O CHA; (D) REPRESENTA ILE, VAL, AIB, TLEU, GLY O LEU; (E) REPRESENTA LYS O ARG; (F) REPRESENTA ILE, LEU O MET; (G) REPRESENTA SER O ALA; (H) REPRESENTA MET O GLN; (I) REPRESENTA -OH, -ASN-OH, -ASN-SER-OH, -ASN-SER-PHE-OH, -ASN-SER-PHE-ARG -OH O -ASN-SER-PHE-ARG-TYR-OH; Y EL SIMBOLO "..." REPRESENTA UN ENLACE DE DIFULSURO; SIEMPRE Y CUANDO 1) ALFA-HANP, 2) ALFA-HANP (7-28) Y 3) CNP-22 SEAN EXCLUIDOS DEL ALCANCE DE ESA FORMULA GENERAL. TAMBIEN SE PRESENTAN LOS AGENTES SUPRESORES DEL CRECIMIENTO DE LAS CELULAS MUSCULARES SUAVES VASCULARES QUE CONTIENEN ESOS PEPTIDOS COMO INGREDIENTES EFECTIVOS.
ES92101621T 1991-01-31 1992-01-31 Peptidos analogos de cnp y su utilizacion. Expired - Lifetime ES2178634T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1132191 1991-01-31
JP3254066A JP2809533B2 (ja) 1991-01-31 1991-06-28 Ｃｎｐ類似体ペプチド

Publications (1)

Publication Number Publication Date
ES2178634T3 true ES2178634T3 (es) 2003-01-01

Family

ID=26346733

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92101621T Expired - Lifetime ES2178634T3 (es) 1991-01-31 1992-01-31 Peptidos analogos de cnp y su utilizacion.

Country Status (6)

Country Link
US (1) US5434133A (es)
EP (1) EP0497368B1 (es)
JP (1) JP2809533B2 (es)
AT (1) ATE219103T1 (es)
DE (1) DE69232636T2 (es)
ES (1) ES2178634T3 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6360394A (en) * 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5665704A (en) * 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) * 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
EP1118329A4 (en) * 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
DE19903087A1 (de) * 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
WO2004087059A2 (en) * 2003-03-26 2004-10-14 The University Of Texas Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding
CN101208353B (zh) * 2003-06-20 2011-12-14 梅约医学教育与研究基金会 脑利尿钠肽的同种型
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
KR20070007842A (ko) 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
AU2007233116B2 (en) 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
AU2007233123A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8324162B2 (en) 2006-08-08 2012-12-04 Mayo Foundation For Medical Education And Research Diuretic and natriuretic polypeptides lacking the blood pressure lowering property
EP2171053B1 (en) * 2007-07-20 2014-04-23 Mayo Foundation for Medical Education and Research Natriuretic polypeptides
WO2009046873A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Combined use of vasonatrin and gastrin-i as a therapeutic agent
WO2009036448A2 (en) * 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-c agonists
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
EP2432489B1 (en) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
EP2457581B1 (en) 2009-07-23 2014-01-08 Igisu Co., Ltd. Composition comprising cnp or bnp for external preparation for skin for the treatment of dermatitis
WO2011024973A1 (ja) * 2009-08-27 2011-03-03 株式会社 イギス 鼻炎治療剤
WO2012013597A1 (de) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
BR112013018679B1 (pt) 2011-01-21 2022-04-12 Igisu Co. Ltd. Agente para o tratamento da alopecia e uso de um peptídeo natriurético do tipo c
EP3189835B1 (en) * 2011-02-28 2018-07-25 National Cerebral and Cardiovascular Center Medical agent for suppressing malignant tumor metastasis
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
KR20140084201A (ko) 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104059154B (zh) * 2014-05-06 2017-09-29 中国人民解放军第四军医大学 一种新的具有抗心力衰竭作用的钠尿肽嵌合体cnaac
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
PT3328416T (pt) 2015-07-30 2024-04-10 Biomarin Pharm Inc Utilização de variantes do péptido natriurético de tipo c para tratar as displasias esqueléticas
EP3689897A1 (en) 2015-07-31 2020-08-05 Igisu Co., Ltd. A cnp cyclic peptide and a medicament, external preparation and cosmetic containing the cyclic peptide
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
DK3386531T3 (da) 2015-12-08 2022-01-03 Biomarin Pharm Inc Anvendelse af c-type natriuretiske peptidvarianter til behandling af osteoarthritis
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN120435308A (zh) 2022-10-21 2025-08-05 伊莱利利公司 长效利尿钠肽及其用途
KR102866559B1 (ko) 2022-11-02 2025-10-02 노보 노르디스크 에이/에스 Cnp 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496544A (en) * 1983-11-10 1985-01-29 Washington University Atrial Peptides
JPH0672157B2 (ja) * 1984-08-29 1994-09-14 味の素株式会社 新規ペプチド
EP0232078A3 (en) * 1986-01-31 1990-03-14 Merck & Co. Inc. Peptides having anf activity
EP0292256A3 (en) * 1987-05-19 1990-10-03 Merck & Co. Inc. Peptides having anf activity
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
DK380288D0 (da) * 1988-07-07 1988-07-07 Novo Industri As Hidtil ukendet peptider
US5352770A (en) * 1990-04-20 1994-10-04 Hisayuki Matsuo Porcine derived novel physiologically active peptide
JP2801079B2 (ja) * 1990-11-14 1998-09-21 サントリー株式会社 Ａｎｐ関連新規ペプチド

Also Published As

Publication number Publication date
DE69232636D1 (de) 2002-07-18
ATE219103T1 (de) 2002-06-15
JP2809533B2 (ja) 1998-10-08
JPH069688A (ja) 1994-01-18
EP0497368A1 (en) 1992-08-05
EP0497368B1 (en) 2002-06-12
DE69232636T2 (de) 2002-12-05
US5434133A (en) 1995-07-18

Similar Documents

Publication Publication Date Title
DE69232636D1 (de) CNP-Analoge Peptide und ihre Verwendung
CO4750841A1 (es) Compuestos ciclicos, inhibidores de la adhesion
ES2070322T3 (es) Polipeptidos biologicamente activos basados en las secuencias del factor de crecimiento de transformacion beta.
NO905472L (no) Insulinanaloger fra menneske og blandinger som inneholderdem.
CY1110927T1 (el) Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων
NL300013I1 (nl) Nieuwe protein met TNF-remmende werking en hun ber
KR930009591A (ko) 트리-아르기닌 인슐린
NO880494L (no) Syntetiske nonapeptid- og decapeptidanaloger av lhrh som er anvendelige som lhrh-antagonister.
ES2137182T3 (es) Derivados recombinantes del factor viii humano.
DK0466175T3 (da) Porcint CNP-gen og præcursor-protein
NL970008I2 (nl) Derivaat van een weefselplasminogeenactivator.
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
DE69230418D1 (de) GRF-Analoge (Growth Hormone Releasing Factors)
ES8606490A1 (es) Un derivado de polipeptido de interferon-a humano
NO882454L (no) Plasminogen-aktivator.
AU682638B2 (en) Peptide, bronchodilator and blood flow ameliorant
ES2056753A6 (es) Un procedimiento para la produccion de un polipeptido que tiene actividad de factor quemotactico de monocitos humanos.
AR241800A1 (es) Procedimiento para preparar compuestos de eglina y procedimiento para obtener preparados farmaceuticos que incluyan a dichos compuestos de eglina como agente activo.
EP0292257A3 (en) Peptides having anf activity
ES2076933T3 (es) Nuevos sustratos peptidicos.
ES2051939T3 (es) Heteroaromatos fenoxialquilsubstituidos, procedimientos para su obtencion y su empleo para la lucha contra las pestes.
GB1294771A (en) Thyrocalcitonin derivative
ES2062006T3 (es) Un psti humano modificado.
EP0687685A4 (en) PHYSIOLOGICALLY ACTIVE PEPTIDES
ES2101017T3 (es) Antagonistas de bradiquinina para el tratamiento de pancreatitis aguda.